Insider filings

AbCellera Biologics Inc. (ABCL)

Biotechnology, listed on NASDAQ.

24 insider transactionslast filed Nov 16, 2026

Share
Download on the App StoreGet it on Google Play

Free on iOS and Android

Scan to get
the app

Insider buyingForm 4 · filed Nov 12, 2026

Thermopylae Holdings, a 10% holder, bought $699K on Nov 12.

One open-market purchase reported on Form 4. CFO Andrew Booth bought $97K on Nov 13.

Nov 12Thermopylae Holdings$699K
Nov 13Andrew Booth$97K

Each bar is one Form 4 filing, as the table below lists it; the lit bar is the one the statement names.

10 open-market purchases.

Filed the same day as the trade, at the median. Form 4 is due within two business days.

Every filing

EarningsQ3 FY2026 · reported Nov 9, 2026

Q3 FY2026: EPS beat, GAAP. Revenue beat by 26.4%. Next report Feb 23, 2027.

EPS Q3 FY2026

Reported-$0.13
Consensus-$0.17

Revenue Q3 FY2026

Reported$10.6M
Consensus$8.42M

Beat 4Miss 2

EPS against the consensus, quarter by quarter. Outlined: a GAAP figure against an adjusted consensus.

Consensus -$0.16 a share on $8.54M of revenue, the analysts’ forecast.

Every quarter
Companyfrom the company's filings and listing, as of Nov 21, 2026

About AbCellera Biologics Inc.

Exchange
NASDAQ
Sector
Healthcare
Industry
Biotechnology
Chief executive
Carl Hansen
Employees
562
Listed since
Dec 11, 2020
Market value
$3.2B
Price to earnings (12 mo)
-
Net income per share, as reported (12 mo)
-$0.47
Dividend yield
-

www.abcellera.com

GetSignal News3 articles · newest first

GetSignal News

HeadlineSourceDate
AbCellera Biologics prices $200 million offering of common shares and pre-funded warrantsAbCellera Biologics said gross proceeds are expected to be approximately $200 million, before underwriting discounts and offering expenses.Form 8-KAug 13, 2026
AbCellera Biologics appoints Lynn Seely to its board of directorsSeely is president and CEO of Lyell Immunopharma Inc. and was previously CEO of Myovant Sciences Inc.Form 8-KJul 6, 2026
AbCellera Biologics shareholders elect two Class III directorsThe meeting covered 305,264,947 common shares outstanding and entitled to vote as of the April 15, 2026 record date.Form 8-KJun 12, 2026

Written by GetSignal with AI from SEC filings and the company's own press releases; each article links to its source. Not investment advice.

All company news

Earnings6 reported quarters · next on Feb 23, 2027

Earnings

QuarterEPSEPS expectedRevenueRevenue expectedResult
Q3 FY2026reported Nov 9, 2026-$0.13-$0.17$10.6M$8.4MEPS beat, GAAPRevenue beat
Q2 FY2026reported Aug 5, 2026-$0.18-$0.16$4.0M$7.8MEPS miss, GAAPRevenue miss
Q1 FY2026reported May 11, 2026-$0.14-$0.22$8.3M$5.4MEPS beat, GAAPRevenue beat
Q4 FY2025reported Feb 24, 2026-$0.03-$0.18$44.9M$6.7MEPS beatRevenue beat
Q3 FY2025reported Nov 6, 2025-$0.19-$0.17$9.0M$6.3MEPS miss, GAAPRevenue beat
Q2 FY2025reported Aug 7, 2025-$0.12-$0.17$17.1M$6.4MEPS beat, GAAPRevenue beat

Actual against the consensus estimate at the time. A flag marks a beat or a miss of more than 1.5% either way; inside that band the quarter is in line. A flag marked GAAP compares a GAAP figure the company reported with an adjusted consensus, two different measures, so a one-time gain or charge can move it either way. A flag reads n/a only when a number is missing. Quarterly EPS is the figure set against the consensus, usually adjusted, so the quarters need not add up to the 12-month net income per share above. An estimate is a forecast made by analysts, not a company target.

No earnings call briefs on ABCL yet. All earnings call briefs.

Proxy statementas filed for fiscal 2025 · proxy filed Apr 29, 2026

Executive pay

Carl L.G. Hansen’s pay came to $6.3M for fiscal 2025.
ExecutiveSalaryStock awardsOtherTotal
Carl L.G. HansenPh.D. :: Chief Executive Officer$550K$0$5.7M$6.3M
Andrew BoothChief Financial Officer$485K$0$2.9M$3.4M
Tryn StimartChief Legal Officer, Chief Compliance Officer, Corporate Secretary, and Privacy Officer$470K$0$1.9M$2.3M
Véronique Lecault, Ph.D.Chief Technology Officer$454K$0$1.9M$2.3M

The summary compensation table from the proxy statement for fiscal 2025, with titles as filed then. Executives who have since left are not shown. Read the filing

13F filings13F positions as of Sep 30, 2026

Institutional holders

HolderValueSharesShares vs prior qtr% of shares out
Baker Bros. Advisors LP$481.6M33,012,1390.0%10.80%
Capital World Investors$198.1M13,579,116-0.1%4.44%
Two Sigma Investments, LP$170.7M11,702,431+12.1%3.83%
Marshall Wace, LLP$130.7M8,958,273+370.9%2.93%
BlackRock, Inc.$82.6M5,660,637+48.8%1.85%
Arrowmark Colorado Holdings LLC$70.4M4,823,182+17.5%1.58%
Bank of America Corp$61.0M4,183,225-31.9%1.37%
D. E. Shaw & Co., Inc.$53.4M3,658,344+7952.5%1.20%
Alyeska Investment Group, L.P.$44.7M3,063,974+481.9%1.00%
Driehaus Capital Management LLC$41.4M2,835,020-1.0%0.93%
Millennium Management LLC$29.7M2,038,187+293.0%0.67%
Arrowstreet Capital, Limited Partnership$29.4M2,013,668+93.6%0.66%

A 13F reports long US equity positions and is filed within 45 days of the quarter end, so these are positions as they stood on Sep 30, 2026. For a manager's whole book see the fund directory. What a 13F covers and leaves out is explained in our guide to Form 13F.

Form 410 filings shown · newest filing first

Open-market insider trades

InsiderActionSharesPriceValueTrade dateDelay
(business days)
Thermopylae Holdings Ltd.10% ownerBought60,565$11.54$699KNov 12, 2026filed Nov 12, 20260d
Andrew BoothChief Financial OfficerBought8,600$11.33$97KNov 13, 2026filed Nov 13, 20260d
Michael R. HaydenDirectorBought53,613$10.64$570KAug 24, 2026filed Aug 24, 20260d
John S. MontalbanoDirectorBought10,000$11.03$110KAug 18, 2026filed Aug 18, 20260d
Michael R. HaydenDirectorBought46,387$10.37$481KAug 12, 2026filed Aug 14, 20262d
Andrew BoothChief Financial OfficerBought37,200$10.32$384KAug 14, 2026filed Aug 14, 20260d
John S. MontalbanoDirectorBought20,000$4.77$95KMay 14, 2026filed May 18, 20262d
Thermopylae Holdings Ltd.10% ownerBought38,000$3.44$131KFeb 27, 2026filed Mar 2, 20261d
Andrew BoothChief Financial OfficerBought42,600$3.42$146KFeb 27, 2026filed Feb 27, 20260d
Thermopylae Holdings Ltd.10% ownerBought177,457$3.27$580KFeb 26, 2026filed Feb 27, 20261d

One row is one filing, newest filing first. A filing that reported its trade in several tranches is summed, priced at the weighted average, and marked with its line count. The delay counts business days from the trade to the filing, the unit of Form 4's two business day deadline: weekends and federal holidays are skipped. How the filing itself works is explained in our guide to Form 4.

Other Form 4 activity (14)
InsiderEventSharesDate
Andrew BoothChief Financial OfficerGift50,000Nov 13, 2026
Andrew BoothChief Financial OfficerOption exercise50,000Nov 13, 2026
Thermopylae Holdings Ltd.10% ownerGift125,000Nov 13, 2026
Michael R. HaydenDirectorGift50,000Aug 11, 2026
Victor SandorDirectorStock award152,207Jul 1, 2026
Lynn SeelyDirectorStock award152,207Jul 1, 2026
John S. MontalbanoDirectorStock award111,701Jun 11, 2026
Stephen QuakeDirectorStock award111,701Jun 11, 2026
Michael R. HaydenDirectorStock award111,701Jun 11, 2026
Veronique LecaultChief Technology OfficerStock award539,265Jan 1, 2026
Tryn StimartChief Legal OfficerStock award539,265Jan 1, 2026
Carl L. G. HansenChief Executive OfficerStock award2,106,505Jan 1, 2026
Andrew BoothChief Financial OfficerStock award808,898Jan 1, 2026
Stephen QuakeDirectorStock award194,932Dec 1, 2025

Awards, option exercises, shares withheld to cover tax and gifts all file on the same form as a purchase or a sale. None of them is a decision to trade, so they sit here rather than beside the ones that are.

Congress rows disclose a value range rather than an exact amount, and the STOCK Act allows up to 45 days to report. Full sourcing and the limits of this data are on the methodology page. A filing is a record of a transaction, not a signal, and nothing here is investment advice.

On Form 4, code P is an open-market purchase and S an open-market sale; a sale marked scheduled was set up in advance under a Rule 10b5-1 plan. Awards, option exercises, tax withholding and gifts (A, M, F and G) are listed under Other Form 4 activity and never counted as either.

Data as of Nov 21, 2026.

Methodology · Guide to Form 4 · Guide to the STOCK Act

Questions

What the filings on ABCL show and how current they are.

Are insiders buying or selling ABCL?

Across the 10 most recent open-market filings shown here, 10 were purchases and 0 were sales.

How quickly are ABCL trades disclosed?

Insider filings on this page reached the public a median of 0 business days after the transaction (weekends and federal holidays skipped), against the two business days Form 4 allows.

Related companies

also in Healthcare

Stocks A to Z